gadolinium dtpa has been researched along with Bilirubinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, H; Atsukawa, M; Ikejima, K; Nagahara, A; Nakadera, E; Okubo, H; Okubo, T | 1 |
| Ando, H; Fukada, H; Ikejima, K; Miyazaki, A; Morishige, J; Nakadera, E; Okubo, H; Sorin, Y | 1 |
2 other study(ies) available for gadolinium dtpa and Bilirubinemia
| Article | Year |
|---|---|
Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment.
Topics: Aminoisobutyric Acids; Bilirubin; Cyclopropanes; Gadolinium DTPA; Hepacivirus; Hepatitis C; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Leucine; Magnetic Resonance Imaging; Proline; Quinoxalines; Sulfonamides | 2022 |
Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Cyclopropanes; Female; Gadolinium DTPA; Hepatitis C; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Middle Aged; Proline; Prospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2018 |